U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07710014) titled 'Evaluation of Foquest in Adults 65 Years and Older With ADHD' on July 08.
Brief Summary: This study is evaluating the safety and effectiveness of Foquest (multilayer-release methylphenidate), a once-daily extended-release medication for attention-deficit/hyperactivity disorder (ADHD), in adults aged 65 years and older.
ADHD can persist into older age and is associated with reduced quality of life and difficulties with executive function. Foquest is currently approved in Canada for the treatment of ADHD in adults up to age 65, but there is very limited research on its use in older adults. People over 65 may respond differently to st...